A Phase 2/3 interventional study of Vatiquinone and Placebo in Mitochondrial Diseases, Drug Resistant Epilepsy and Leigh Disease, sponsored by PTC Therapeutics. Terminated at 27 sites in 9 countries. Open to participants aged Up to 20 Years. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by PTC Therapeutics · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Mitochondrial Diseases with a site in United States — 20 open to participants now, 22 under way, 3 of them phase 3. Mitochondrial Diseases · United States.
Among the 83 studies in Mitochondrial Diseases with a site in United States, this one is the 15th largest by enrollment of the 50 interventional ones that give a count, is one of 6 that started in 2020, is the only one in phase 2/3, and was the 60th registered.
189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.
Browse Mitochondrial Diseases studies →20 of the 83 studies in Mitochondrial Diseases with a site in United States are open now. Recruiting first, the newest first:
Pharming Technologies B.V. · Sites in United States, Belgium, Czechia and 6 more countries
Ages 18+
Khondrion BV · Sites in United States, Denmark, France and 4 more countries
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 8–75 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 18–65 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.
This study: Up to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 21 · Phase 3 11 · Phase 4 3
First in 2000; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 35 across 114 interventional studies indexed under Mitochondrial Diseases.
Median enrollment 38 across the 50 interventional studies, 61 across the 31 observational. Of the 54 that completed or were terminated, 23 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
PTC Therapeutics is the lead sponsor of 65 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.
PTC Therapeutics has 6 studies filed under Mitochondrial Diseases — fewer than ten, so there is no comparison to draw.
9 of the studies in Mitochondrial Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT03639701Columbia UniversityTreatment of TK2 Deficiency With Thymidine and Deoxycytidine | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 83 studies in Mitochondrial Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase. After completion of the randomized, placebo-controlled phase, participants may enter a 48-week, long-term, extension phase during which they will receive open-label treatment with vatiquinone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Despite ongoing treatment with at least 2 antiepileptic drugs:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 milligrams/kilogram (mg/kg) if body weight \<13 kg, and 200 mg if body weight ≥13 kg, administered orally, 3 times per day (TID) or up to 72 weeks
Drug: Vatiquinone · Other: Placebo
Vatiquinone-matching placebo, administered orally, TID for up to 24 weeks followed by vatiquinone 15 mg/kg if body weight \<13 kg, and 200 mg if body weight ≥13 kg, administered orally, TID for up to 48 weeks.
Other: Placebo
Vatiquinone will be administered per the treatment arm description.
Also known as: PTC743, EPI-743
Vatiquinone-matching placebo will be administered per the treatment arm description
Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period
The 28-day motor seizure frequency in the double-blind period was calculated as the (number of motor seizures)/ (the number of valid days where motor seizure count information is present) \* 28 within the double-blind period. The baseline of the seizure frequency used the 28 days observations immediately prior to treatment start date for this calculation.
Time frame: Baseline to Week 24
Change From Baseline to Week 24 in Number of Disease-Related Hospitalization Days Per 28 Days in Double-Blind Period
The disease-related hospitalization days per 28 days in the double-blind period was calculated as the (number of disease-related hospitalizations)/(the number of days within the double-blind period) \* 28. The baseline hospitalization used the 28 days observations immediately prior to treatment start date for this calculation.
Time frame: Baseline to Week 24
Change From Baseline to Week 72 in Number of Disease-Related Hospitalization Days Per 28 Days in Overall Period
The disease-related hospitalization days per 28 days in the overall period was calculated as the (number of disease-related hospitalizations)/(the number of days within the overall treatment period) \* 28. The baseline hospitalization used the 28 days observations immediately prior to treatment start date for this calculation.
Time frame: Baseline to Week 72
Change From Baseline to Week 24 in Occurrence/Recurrence of Status Epilepticus Per 28 Days in Double-blind Period
The status epilepticus per 28 Days in the double-blind period was calculated as the (number of status epilepticus incidences)/(the number of days in the double-blind period) \* 28. The baseline status epilepticus incidences used the 28 days observations immediately prior to treatment start date for this calculation.
Time frame: Baseline to Week 24
Change From Baseline to Week 72 in Occurrence/Recurrence of Status Epilepticus Per 28 Days in Overall Period
The status epilepticus per 28 Days in the overall period was calculated as the (number of status epilepticus incidences)/(the number of days in the overall period) \* 28. The baseline status epilepticus incidences used the 28 days observations immediately prior to treatment start date for this calculation.
Time frame: Baseline to Week 72
Number of Participants With Disease-Related In-Patient Hospitalizations in Double-Blind Period
In-patient hospitalization per 28 days in the double-blind period was calculated as the (number of in-patient hospitalization)/(the number of days in the double-blind period) \* 28. The baseline in-patient hospitalization used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with in-patient hospitalizations for either seizure or epilepticus per 28 days in double-blind period are reported.
Time frame: Baseline to Week 24
Number of Participants With Disease-Related In-Patient Hospitalizations in Overall Period
In-patient hospitalization per 28 days in the overall period was calculated as the (number of in-patient hospitalization)/(the number of days in the overall period) \* 28. The baseline in-patient hospitalization used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with in-patient hospitalizations for either seizure or epilepticus per 28 days in overall period are reported.
Time frame: Baseline to Week 72
Number of Participants With Disease-Related Emergency Room Visits in Double-Blind Period
Disease-related emergency room visits per 28 days in the double-blind period was calculated as the (number of disease-related emergency room visits)/(the number of days in the double-blind period) \* 28. The baseline disease-related emergency room visits used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with disease-related emergency room visits for either seizure or epilepticus per 28 days in double-blind period are reported.
Time frame: Baseline to Week 24
Number of Participants With Disease-Related Emergency Room Visits in Overall Period
Disease-related emergency room visits per 28 days in the overall period was calculated as the (number of disease-related emergency room visits)/(the number of days in the overall period) \* 28. The baseline disease-related emergency room visits used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with disease-related emergency room visits for either seizure or epilepticus per 28 days in overall period are reported.
Time frame: Baseline to Week 72
Number of Disease-Related In-Patient Hospitalizations in Double-Blind Period
In-patient hospitalization per 28 days in the double-blind period was calculated as the (number of in-patient hospitalization)/(the number of days in the double-blind period) \* 28. The baseline in-patient hospitalization used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with number of in-patient hospitalizations for either seizure or epilepticus per 28 days in double-blind period are reported.
Time frame: Baseline to Week 24
Number of Disease-Related In-Patient Hospitalizations in Overall Period
In-patient hospitalization per 28 days in the overall period was calculated as the (number of in-patient hospitalization)/(the number of days in the overall period) \* 28. The baseline in-patient hospitalization used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with number in-patient hospitalizations for either seizure or epilepticus per 28 days in overall period are reported.
Time frame: Baseline to Week 72
Number of Disease-Related Emergency Room Visits in Double-Blind Period
Disease-related emergency room visits per 28 days in the double-blind period was calculated as the (number of disease-related emergency room visits)/(the number of days in the double-blind period) \* 28. The baseline disease-related emergency room visits used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with number of emergency room visits for either seizure or epilepticus per 28 days in double-blind period are reported.
Time frame: Baseline to Week 24
Number of Disease-Related Emergency Room Visits in Overall Period
Disease-related emergency room visits per 28 days in the overall period was calculated as the (number of disease-related emergency room visits)/(the number of days in the overall period) \* 28. The baseline disease-related emergency room visits used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with number of emergency room visits for either seizure or epilepticus per 28 days in overall period are reported.
Time frame: Baseline to Week 72
Percent Change From Baseline to Week 24 in Total Seizure Frequency Per 28 Days in Double-Blind Period
The total seizure frequency per 28 days in the double-blind period was calculated as the (number of total seizures)/(the number of valid days where total seizure count information is present) \* 28 within the double-blind period. The baseline of the seizure frequency used the 28 days observations immediately prior to treatment start date for this calculation.
Time frame: Baseline, Week 24
Percent Change From Baseline to Week 72 in Total Seizure Frequency Per 28 Days in Overall Period
Overall period was defined as the period from the first dosing date of investigational product (IP) during double-blind period to the end of study (double-blind + open-label period). The 28 day total seizure frequency in the overall period was calculated as the (number of total seizures)/(the number of valid days where total seizure count information is present) \* 28 within the overall period. The baseline of the seizure frequency used the 28 days observations immediately prior to treatment start date for this calculation.
Time frame: Baseline, Week 72
Number of Participants Taking Rescue Medications in the Double-blind Period
Number of participants taking rescue medications for epilepsy in double-blind period are reported.
Time frame: Baseline to Week 24
Number of Participants Taking Rescue Medications in the Overall Period
Number of participants taking rescue medications for epilepsy in overall period are reported.
Time frame: Baseline to Week 72
Change From Baseline to Week 24 in Health-Related Quality of Life as Measured by the Care-Related Quality of Life of Informal Caregivers (CarerQoL-7D) Questionnaire Score in Double-blind Period
The CarerQol-7D consists of 5 negative and 2 positive dimensions of providing informal care. The negative dimensions are relational problems, mental health problems, problems combining daily activities with care, financial problems and physical health problems because of providing informal care. The 2 positive dimensions are fulfilment from caregiving and support with lending care. For each dimension, there are 3 possible responses: no, some and a lot. Utility tariffs for CarerQol have been developed to calculate a weighted sum score of CarerQol-7D from the responses on the 7 dimensions, ranging from 0 (worst imaginable caregiving situation) to 100 (best imaginable caregiving situation), for which discrete choice experiments were used. Higher sum scores reflect better care-related quality of life.
Time frame: Baseline, Week 24
Change From Baseline to Week 72 in Health-Related Quality of Life as Measured by the CarerQoL-7D Questionnaire Score in Overall Period
The CarerQol-7D consists of 5 negative and 2 positive dimensions of providing informal care. The negative dimensions are relational problems, mental health problems, problems combining daily activities with care, financial problems and physical health problems because of providing informal care. The 2 positive dimensions are fulfilment from caregiving and support with lending care. For each dimension, there are 3 possible responses: no, some and a lot. Utility tariffs for CarerQol have been developed to calculate a weighted sum score of CarerQol-7D from the responses on the 7 dimensions, ranging from 0 (worst imaginable caregiving situation) to 100 (best imaginable caregiving situation), for which discrete choice experiments were used. Higher sum scores reflect better care-related quality of life.
Time frame: Baseline, Week 72
Number of Participants With Motor Seizure Clusters in Double-Blind Period
Seizure clusters were defined by "too many to count" entries in the seizure diaries. The motor seizure clusters per 28 days in the double-blind period was calculated as the (number of motor seizure clusters)/(the number of valid days where motor seizure clusters count information was present) \* 28 within the double-blind period. The baseline of the seizure frequency used the 28 days observations immediately prior to treatment start date for this calculation.
Time frame: Baseline to Week 24
Number of Participants With Motor Seizure Clusters in Overall Period
Seizure clusters were defined by "too many to count" entries in the seizure diaries. The motor seizure clusters per 28 days in the overall period was calculated as the (number of motor seizure clusters)/(the number of valid days where motor seizure clusters count information was present) \* 28 within the overall period. The baseline of the seizure frequency used the 28 days observations immediately prior to treatment start date for this calculation.
Time frame: Baseline to Week 72
Number of Participants With >30%, 30% to -30%, < -30% to -60%, < -60% to -100% Reduction in Motor Seizures Per 28 Days During the Double-blind Period
Number of participants whose motor seizure frequency reduction per 28 days was more than the specified percentage compared to baseline were reported.
Time frame: Baseline to Week 24
Number of Participants With >30%, 30% to -30%, < -30% to -60%, < -60% to -100% Reduction in Total Seizures Per 28 Days During the Double-blind Period
Number of participants whose total seizure frequency reduction per 28 days was more than the specified percentage compared to baseline were reported.
Time frame: Baseline to Week 24
| Milestone | Double-blind Period: Vatiquinone | Double-blind Period: Placebo | Long-term Extension: Vatiquinone/Vatiquinone | Long-term Extension: Placebo/Vatiquinone |
|---|---|---|---|---|
| Started | 34 | 34 | 0 | 0 |
| Received at least 1 dose of study drug | 34 | 34 | 0 | 0 |
| Completed | 28 | 29 | 0 | 0 |
| Not completed | 6 | 5 | 0 | 0 |
| Withdrew: Adverse event | 2 | 2 | 0 | 0 |
| Withdrew: Death | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Other than specified | 0 | 2 | 0 | 0 |
| Milestone | Double-blind Period: Vatiquinone | Double-blind Period: Placebo | Long-term Extension: Vatiquinone/Vatiquinone | Long-term Extension: Placebo/Vatiquinone |
|---|---|---|---|---|
| Started | 0 | 0 | 28 | 29 |
| Completed | 0 | 0 | 16 | 18 |
| Not completed | 0 | 0 | 12 | 11 |
| Withdrew: Death | 0 | 0 | 2 | 2 |
| Withdrew: Other than specified | 0 | 0 | 9 | 7 |
| Withdrew: Sponsor's decision | 0 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
The 28-day motor seizure frequency in the double-blind period was calculated as the (number of motor seizures)/ (the number of valid days where motor seizure count information is present) \* 28 within the double-blind period. The baseline of the seizure frequency used the 28 days observations immediately prior to treatment start date for this calculation.
| percent change | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period | -12.74 ± -28.67 | -0.33 ± -28.97 |
The disease-related hospitalization days per 28 days in the double-blind period was calculated as the (number of disease-related hospitalizations)/(the number of days within the double-blind period) \* 28. The baseline hospitalization used the 28 days observations immediately prior to treatment start date for this calculation.
| days | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| Change From Baseline to Week 24 in Number of Disease-Related Hospitalization Days Per 28 Days in Double-Blind Period | 0 ± 0 | 0 ± 0 |
The disease-related hospitalization days per 28 days in the overall period was calculated as the (number of disease-related hospitalizations)/(the number of days within the overall treatment period) \* 28. The baseline hospitalization used the 28 days observations immediately prior to treatment start date for this calculation.
| days | Overall Period: Vatiquinone/Vatiquinone | Overall Period: Placebo/Vatiquinone |
|---|---|---|
| Change From Baseline to Week 72 in Number of Disease-Related Hospitalization Days Per 28 Days in Overall Period | 0.363 (0 to 1.304) | 0.166 (0 to 0.515) |
The status epilepticus per 28 Days in the double-blind period was calculated as the (number of status epilepticus incidences)/(the number of days in the double-blind period) \* 28. The baseline status epilepticus incidences used the 28 days observations immediately prior to treatment start date for this calculation.
| status epilepticus per 28 days | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| Change From Baseline to Week 24 in Occurrence/Recurrence of Status Epilepticus Per 28 Days in Double-blind Period | 0.039 ± 0.9564 | -0.026 ± 1.1083 |
The status epilepticus per 28 Days in the overall period was calculated as the (number of status epilepticus incidences)/(the number of days in the overall period) \* 28. The baseline status epilepticus incidences used the 28 days observations immediately prior to treatment start date for this calculation.
| status epilepticus per 28 days | Overall Period: Vatiquinone/Vatiquinone | Overall Period: Placebo/Vatiquinone |
|---|---|---|
| Change From Baseline to Week 72 in Occurrence/Recurrence of Status Epilepticus Per 28 Days in Overall Period | 0.036 ± 0.6444 | -0.102 ± 1.0094 |
In-patient hospitalization per 28 days in the double-blind period was calculated as the (number of in-patient hospitalization)/(the number of days in the double-blind period) \* 28. The baseline in-patient hospitalization used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with in-patient hospitalizations for either seizure or epilepticus per 28 days in double-blind period are reported.
| Participants | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| Number of Participants With Disease-Related In-Patient Hospitalizations in Double-Blind Period | 6 | 2 |
In-patient hospitalization per 28 days in the overall period was calculated as the (number of in-patient hospitalization)/(the number of days in the overall period) \* 28. The baseline in-patient hospitalization used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with in-patient hospitalizations for either seizure or epilepticus per 28 days in overall period are reported.
| Participants | Overall Period: Vatiquinone/Vatiquinone | Overall Period: Placebo/Vatiquinone |
|---|---|---|
| Number of Participants With Disease-Related In-Patient Hospitalizations in Overall Period | 11 | 3 |
Disease-related emergency room visits per 28 days in the double-blind period was calculated as the (number of disease-related emergency room visits)/(the number of days in the double-blind period) \* 28. The baseline disease-related emergency room visits used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with disease-related emergency room visits for either seizure or epilepticus per 28 days in double-blind period are reported.
| Participants | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| Number of Participants With Disease-Related Emergency Room Visits in Double-Blind Period | 9 | 4 |
Disease-related emergency room visits per 28 days in the overall period was calculated as the (number of disease-related emergency room visits)/(the number of days in the overall period) \* 28. The baseline disease-related emergency room visits used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with disease-related emergency room visits for either seizure or epilepticus per 28 days in overall period are reported.
| Participants | Overall Period: Vatiquinone/Vatiquinone | Overall Period: Placebo/Vatiquinone |
|---|---|---|
| Number of Participants With Disease-Related Emergency Room Visits in Overall Period | 14 | 5 |
In-patient hospitalization per 28 days in the double-blind period was calculated as the (number of in-patient hospitalization)/(the number of days in the double-blind period) \* 28. The baseline in-patient hospitalization used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with number of in-patient hospitalizations for either seizure or epilepticus per 28 days in double-blind period are reported.
| Participants | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| 0 Hospitalization | 28 | 32 |
| 1 Hospitalization | 4 | 1 |
| 2 Hospitalizations | 1 | 0 |
| 7 Hospitalizations | 0 | 1 |
| 10 Hospitalizations | 1 | 0 |
In-patient hospitalization per 28 days in the overall period was calculated as the (number of in-patient hospitalization)/(the number of days in the overall period) \* 28. The baseline in-patient hospitalization used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with number in-patient hospitalizations for either seizure or epilepticus per 28 days in overall period are reported.
| Participants | Overall Period: Vatiquinone/Vatiquinone | Overall Period: Placebo/Vatiquinone |
|---|---|---|
| 0 Hospitalization | 23 | 31 |
| 1 Hospitalization | 7 | 1 |
| 2 Hospitalizations | 0 | 1 |
| 5 Hospitalizations | 1 | 0 |
| 6 Hospitalizations | 1 | 0 |
| 7 Hospitalizations | 0 | 1 |
| 8 Hospitalizations | 1 | 0 |
| 10 Hospitalizations | 1 | 0 |
Disease-related emergency room visits per 28 days in the double-blind period was calculated as the (number of disease-related emergency room visits)/(the number of days in the double-blind period) \* 28. The baseline disease-related emergency room visits used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with number of emergency room visits for either seizure or epilepticus per 28 days in double-blind period are reported.
| Participants | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| 0 Visit | 25 | 30 |
| 1 Visit | 7 | 4 |
| 2 Visits | 1 | 0 |
| 10 Visits | 1 | 0 |
Disease-related emergency room visits per 28 days in the overall period was calculated as the (number of disease-related emergency room visits)/(the number of days in the overall period) \* 28. The baseline disease-related emergency room visits used the 28 days observations immediately prior to treatment start date for this calculation. Number of participants with number of emergency room visits for either seizure or epilepticus per 28 days in overall period are reported.
| Participants | Overall Period: Vatiquinone/Vatiquinone | Overall Period: Placebo/Vatiquinone |
|---|---|---|
| 0 Visit | 20 | 29 |
| 1 Visit | 8 | 4 |
| 2 Visits | 2 | 1 |
| 6 Visits | 2 | 0 |
| 8 Visits | 1 | 0 |
| 10 Visits | 1 | 0 |
The total seizure frequency per 28 days in the double-blind period was calculated as the (number of total seizures)/(the number of valid days where total seizure count information is present) \* 28 within the double-blind period. The baseline of the seizure frequency used the 28 days observations immediately prior to treatment start date for this calculation.
| percent change | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| Percent Change From Baseline to Week 24 in Total Seizure Frequency Per 28 Days in Double-Blind Period | -14.27 ± -34.52 | -5.73 ± -31.59 |
Overall period was defined as the period from the first dosing date of investigational product (IP) during double-blind period to the end of study (double-blind + open-label period). The 28 day total seizure frequency in the overall period was calculated as the (number of total seizures)/(the number of valid days where total seizure count information is present) \* 28 within the overall period. The baseline of the seizure frequency used the 28 days observations immediately prior to treatment start date for this calculation.
| percent change | Overall Period: Vatiquinone/Vatiquinone | Overall Period: Placebo/Vatiquinone |
|---|---|---|
| Percent Change From Baseline to Week 72 in Total Seizure Frequency Per 28 Days in Overall Period | -17.03 (-42.38 to 0) | -7.52 (-35.46 to 17.00) |
Number of participants taking rescue medications for epilepsy in double-blind period are reported.
| Participants | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| Number of Participants Taking Rescue Medications in the Double-blind Period | 24 | 22 |
Number of participants taking rescue medications for epilepsy in overall period are reported.
| Participants | Overall Period: Vatiquinone/Vatiquinone | Overall Period: Placebo/Vatiquinone |
|---|---|---|
| Number of Participants Taking Rescue Medications in the Overall Period | 24 | 23 |
The CarerQol-7D consists of 5 negative and 2 positive dimensions of providing informal care. The negative dimensions are relational problems, mental health problems, problems combining daily activities with care, financial problems and physical health problems because of providing informal care. The 2 positive dimensions are fulfilment from caregiving and support with lending care. For each dimension, there are 3 possible responses: no, some and a lot. Utility tariffs for CarerQol have been developed to calculate a weighted sum score of CarerQol-7D from the responses on the 7 dimensions, ranging from 0 (worst imaginable caregiving situation) to 100 (best imaginable caregiving situation), for which discrete choice experiments were used. Higher sum scores reflect better care-related quality of life.
| units on a scale | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| Change From Baseline to Week 24 in Health-Related Quality of Life as Measured by the Care-Related Quality of Life of Informal Caregivers (CarerQoL-7D) Questionnaire Score in Double-blind Period | -10.38 ± 18.207 | -5.25 ± 10.112 |
The CarerQol-7D consists of 5 negative and 2 positive dimensions of providing informal care. The negative dimensions are relational problems, mental health problems, problems combining daily activities with care, financial problems and physical health problems because of providing informal care. The 2 positive dimensions are fulfilment from caregiving and support with lending care. For each dimension, there are 3 possible responses: no, some and a lot. Utility tariffs for CarerQol have been developed to calculate a weighted sum score of CarerQol-7D from the responses on the 7 dimensions, ranging from 0 (worst imaginable caregiving situation) to 100 (best imaginable caregiving situation), for which discrete choice experiments were used. Higher sum scores reflect better care-related quality of life.
| units on a scale | Overall Period: Vatiquinone/Vatiquinone | Overall Period: Placebo/Vatiquinone |
|---|---|---|
| Change From Baseline to Week 72 in Health-Related Quality of Life as Measured by the CarerQoL-7D Questionnaire Score in Overall Period | -0.95 ± 14.235 | -3.14 ± 13.675 |
Seizure clusters were defined by "too many to count" entries in the seizure diaries. The motor seizure clusters per 28 days in the double-blind period was calculated as the (number of motor seizure clusters)/(the number of valid days where motor seizure clusters count information was present) \* 28 within the double-blind period. The baseline of the seizure frequency used the 28 days observations immediately prior to treatment start date for this calculation.
| Participants | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| Number of Participants With Motor Seizure Clusters in Double-Blind Period | 19 | 25 |
Seizure clusters were defined by "too many to count" entries in the seizure diaries. The motor seizure clusters per 28 days in the overall period was calculated as the (number of motor seizure clusters)/(the number of valid days where motor seizure clusters count information was present) \* 28 within the overall period. The baseline of the seizure frequency used the 28 days observations immediately prior to treatment start date for this calculation.
| Participants | Overall Period: Vatiquinone/Vatiquinone | Overall Period: Placebo/Vatiquinone |
|---|---|---|
| Number of Participants With Motor Seizure Clusters in Overall Period | 21 | 26 |
Number of participants whose motor seizure frequency reduction per 28 days was more than the specified percentage compared to baseline were reported.
| Participants | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| >30% | 7 | 9 |
| 30% to -30% | 17 | 14 |
| < -30% to -60% | 7 | 7 |
| < -60% to -100% | 3 | 4 |
Number of participants whose total seizure frequency reduction per 28 days was more than the specified percentage compared to baseline were reported.
| Participants | Double-blind Period: Vatiquinone | Double-blind Period: Placebo |
|---|---|---|
| >30% | 7 | 7 |
| 30% to -30% | 13 | 15 |
| < -30% to -60% | 10 | 9 |
| < -60% to -100% | 4 | 3 |
Collected over Baseline up to Week 77. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Period: Vatiquinone | 3/34 (8.8%) | 18/34 (52.9%) | 26/34 (76.5%) |
| Double-blind Period: Placebo | 0/34 (0%) | 9/34 (26.5%) | 20/34 (58.8%) |
| On-Vatiquinone Period: Vatiquinone/Vatiquinone | 5/34 (14.7%) | 26/34 (76.5%) | 30/34 (88.2%) |
| On-Vatiquinone Period: Placebo/Vatiquinone | 2/29 (6.9%) | 16/29 (55.2%) | 19/29 (65.5%) |
| Event | Double-blind Period: Vatiquinone | Double-blind Period: Placebo | On-Vatiquinone Period: Vatiquinone/Vatiquinone | On-Vatiquinone Period: Placebo/Vatiquinone |
|---|---|---|---|---|
| SeizureNervous system disorders | 4/34 | 0/34 | 7/34 | 1/29 |
| COVID-19Infections and infestations | 2/34 | 0/34 | 5/34 | 0/29 |
| PneumoniaInfections and infestations | 2/34 | 2/34 | 2/34 | 4/29 |
| VomitingGastrointestinal disorders | 1/34 | 1/34 | 3/34 | 1/29 |
| Rhinovirus infectionInfections and infestations | 1/34 | 1/34 | 3/34 | 0/29 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/34 | 0/34 | 3/34 | 2/29 |
| Pneumonia aspirationInfections and infestations | 0/34 | 0/34 | 2/34 | 2/29 |
| Status epilepticusNervous system disorders | 1/34 | 2/34 | 2/34 | 0/29 |
| DeathGeneral disorders | 1/34 | 0/34 | 1/34 | 1/29 |
| InfluenzaInfections and infestations | 1/34 | 0/34 | 1/34 | 1/29 |
| Event | Double-blind Period: Vatiquinone | Double-blind Period: Placebo | On-Vatiquinone Period: Vatiquinone/Vatiquinone | On-Vatiquinone Period: Placebo/Vatiquinone |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 7/34 | 0/34 | 10/34 | 1/29 |
| PyrexiaGeneral disorders | 4/34 | 1/34 | 9/34 | 1/29 |
| Upper respiratory tract infectionInfections and infestations | 2/34 | 3/34 | 5/34 | 7/29 |
| SeizureNervous system disorders | 4/34 | 1/34 | 8/34 | 1/29 |
| Ear infectionInfections and infestations | 1/34 | 0/34 | 4/34 | 0/29 |
| SinusitisInfections and infestations | 1/34 | 0/34 | 4/34 | 0/29 |
| Urinary tract infectionInfections and infestations | 3/34 | 2/34 | 4/34 | 2/29 |
| ContusionInjury, poisoning and procedural complications | 2/34 | 0/34 | 4/34 | 0/29 |
| InfluenzaInfections and infestations | 1/34 | 1/34 | 2/34 | 3/29 |
| COVID-19Infections and infestations | 1/34 | 0/34 | 3/34 | 2/29 |
Intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of treatment.
| Age, Continuous(years) | Double-blind Period: Vatiquinone | Double-blind Period: Placebo | Total |
|---|---|---|---|
| Mean | 8.7 ± 5.34 | 6.6 ± 4.84 | 7.6 ± 5.17 |
| Sex: Female, Male(Participants) | Double-blind Period: Vatiquinone | Double-blind Period: Placebo | Total |
|---|---|---|---|
| Female | 14 | 20 | 34 |
| Male | 20 | 14 | 34 |
| Ethnicity (NIH/OMB)(Participants) | Double-blind Period: Vatiquinone | Double-blind Period: Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 26 | 30 | 56 |
| Unknown or Not Reported | 6 | 3 | 9 |
| Race/Ethnicity, Customized(Participants) | Double-blind Period: Vatiquinone | Double-blind Period: Placebo | Total |
|---|---|---|---|
| Race — American Indian/Alaska Native | 0 | 1 | 1 |
| Race — Asian | 3 | 9 | 12 |
| Race — Black/African American | 1 | 3 | 4 |
| Race — White/Caucasian | 24 | 20 | 44 |
| Race — Other | 1 | 0 | 1 |
| Race — Not Reported | 5 | 1 | 6 |
| Number of Observable Motor Seizures per 28 Days(motor seizures/28 days) | Double-blind Period: Vatiquinone | Double-blind Period: Placebo | Total |
|---|---|---|---|
| Median | 112.5 (6 to 3139) | 237.0 (15 to 2918) | 164.0 (64.5 to 391.0) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Sep 2020 to primary completion in Mar 2023, 29 months.
Results were first posted in Mar 2026, 3 years after primary completion. A results delay was requested in Mar 2024.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha-tocotrienol quinone